Comparative analysis of cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells

Chemotherapy

Volumn 54, Issue 3, 2008, Pages 217-223

  Kitada, Noriaki ^a   Takara, Kohji ^a   Itoh, Chihiro ^a   Minegaki, Tetsuya ^a   Tsujimoto, Masayuki ^a   Sakaeda, Toshiyuki ^b   Yokoyama, Teruyoshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Cisplatin; LLC PK 1 cell; Nedaplatin; Nephrotoxicity; Oxaliplatin

Indexed keywords

CARBOPLATIN; CASPASE 3; CISPLATIN; LACTATE DEHYDROGENASE; NEDAPLATIN; OXALIPLATIN; PLATINUM; PLATINUM DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG ACCUMULATION; DRUG EXCRETION; ENZYME ACTIVITY; EPITHELIUM CELL; KIDNEY TUBULE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SWINE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL DEATH; CELL LINE; CELL SHAPE; ENZYME ACTIVATION; EPITHELIAL CELLS; HYDRO-LYASES; KIDNEY TUBULES; PLATINUM; SWINE;

EID: 46449102593     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140465     Document Type: Article

References (36)

1. Ho YP, Au-Yeung SC, To KK: Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 2003;23:633-655.
2. Yonezawa A, Masuda S, Yokoo S, et al: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-886.
3. Armand JP, Bolgie V, Raymond E, et al: Oxaliplatin in colorectal cancer: an overview. Semin Oncol 2000;27(suppl 10):96-104.
4. Kidani Y, Noji M, Tashiro T: Antitumor activity of platinum (II) complexes of 1,2-diaminocyclohexane isomers. Gann 1980;71:637-643.
5. Boulikas T, Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 2004;11:559-595.
6. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003;10:1663-1682.
7. Uehara T, Watanabe H, Itoh F, et al: Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 2005;79:451-460.
8. Stohr W, Paulides M, Bielack S, et al: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2006;48:140-147.
9. Zhou H, Kato A, Miyaji T, et al: Urinary marker for oxidative stress in kidneys in cisplatin-induced acute renal failure in rats. Nephrol Dial Transplant 2006;21:616-623.
10. Takara K, Tsujimoto M, Kokufu M, et al: Upregulation of MDR1 function and expression by cisplatin in LLC-PK 1 cells. Biol Pharm Bull 2003;26:205-209.
11. Takara K, Sakaeda T, Yagami T, et al: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 2002;25:771-778.
12. Takara K, Tsujimoto M, Ohnishi N, et al: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 2002;292:190-194.
13. Nagasawa K, Ito S, Kakuda T, et al: Transport mechanism for aluminum citrate at the blood-brain barrier: kinetic evidence implies involvement of system Xc- in immortalized rat brain endothelial cells. Toxicol Lett 2005;155:289-296.
14. Lowry OH, Rosebrough NJ, Farr AL, et al: Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
15. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
16. Basnakian AG, Apostolov EO, Yin X, et al: Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol 2005;16:697-702.
17. Kitada N, Takara K, Minegaki T, et al: Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol, in press.
18. 1 cells: in case of carboplatin and nedaplatin. J Cancer Mol 2007;3:23-28.
19. Safaei R: Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006;234:34-39.
20. Holzer AK, Samimi G, Katano K, et al: The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 2004;66:817-823.
21. Samimi G, Katano K, Holzer AK, et al: Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 2004;66:25-32.
22. Ciarimboli G, Ludwig T, Lang D, et al: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-1484.
23. Yokoo S, Yonezawa A, Masuda S, et al: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007;74:477-487.
24. Nakamura T, Kokuryo T, Okuda M, et al: Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK 1 kidney epithelial cells. Pharm Res 1999;16:1132-1135.
25. Mese H, Sasaki A, Alcalde RE, et al: Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Chemotherapy 2000;46:69-76.
26. Watanabe KC, Jinnouchi K, Hess A, et al: Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy 2002;48:82-87.
27. Labaye J, Sarret D, Duvic C, et al: Renal toxicity of oxaliplatin. Nephrol Dial Transplant 2005:20:1275-1276.
28. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-1218.
29. Hanigan MH, Devarajan P: Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003;1:47-61.
30. Sasaki Y, Tamura T, Eguchi K, et al: Pharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 1989;23:243-246.
31. O'Dwyer PJ, Stevenson JP, Johnson SW: Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59:19-27.
32. Urien S, Lokiec F: Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004;57:756-763.
33. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
34. Duffull SB, Robinson BA: Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997;33:161-183.
35. Ishibashi T, Yano Y, Oguma T: Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003;56:205-213.
36. 2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit 2006;28:206-211.